Background: Previous genomewide association studies (GWASs) have identified a number of putative risk loci for alcohol dependence (AD). However, only a few loci have replicated and these replicated variants only explain a small proportion of AD risk. Using an innovative approach, the goal of this study was to generate hypotheses about potentially causal variants for AD that can be explored further through functional studies.
A LCOHOL DEPENDENCE (AD) is a disorder characterized by compulsive and uncontrolled consumption of alcohol despite its negative effects on the drinker's health, relationships, and social standing. Family, adoption, twin, and sibling studies have consistently shown that AD is moderately heritable (Goldman et al., 2005) . Genomewide association studies (GWASs) have identified a number of putative risk loci (Adkins et al., 2015; Edenberg et al., 2010; Frank et al., 2012; Gelernter et al., 2014; Schumann et al., 2011; Treutlein et al., 2009; Zuo et al., 2013b) for populations of European ancestry, the focus of this study. However, only a few loci have replicated (Gelernter et al., 2014; Schumann et al., 2011) and these replicated variants only explain a small proportion of AD risk.
One explanation is that instead of following the common disease common variant hypothesis, which says that the disease-causing variants are common in the population of study and have large effect sizes (Visscher et al., 2012) , there may be multiple rare causal variants for AD (Edenberg and Foroud, 2014) . GWASs would have been unable to detect these rare variants because the analysis methods and technology used are designed to target common variants (Wagner, 2013) . There is precedent for rare variants contributing to complex diseases ranging from breast cancer (Easton et al., 2007) to neuropsychiatric disorders (Heinzen et al., 2015) . In addition, evolutionary theory predicts that disease-causing variants may be rare owing to negative selection and reduced fitness (EyreWalker, 2010) . Indeed, it has been demonstrated that genes involved in the absorption, distribution, metabolism, and excretion of endogenous compounds, such as alcohol, have higher rates of selection because of the role these genes play in defending against foreign chemical substances .
The goal of this paper was to generate hypotheses about potentially causal variants for AD that can be explored further through functional studies. Using an innovative approach, we first deep sequenced entire genes plus flanking regions so that we could explore both common and rare variants and variants located within and outside of exons for association with AD. Next, we formed sets of variants based on biological features that affect protein coding or regulate gene expression, in order to test whether variants with specific features are associated with AD.
Exome sequencing studies (Ng et al., 2009) , which interrogate the protein coding portion of the genome, can detect rare variants, but the AD studies performed to date used arrays and have not detected any significant rare variants (Vrieze et al., 2014; Zuo et al., 2013a) . One possibility for this finding is that the risk variants for AD may lie outside exons, potentially in regions of the genome which regulate gene expression (Buhler et al., 2015) . Indeed, the vast majority (~88%) of GWAS findings for complex diseases are not in exons (Hindorff et al., 2015) . The implication is that entire genes will need to be sequenced, thereby capturing variants both within and outside exons. In the past, it has been difficult to understand how risk variants located outside exons could influence disease. However, large-scale efforts have been undertaken to map the location of and better understand the role of regulatory elements in the human genome, such as the Roadmap Epigenomics Project (Kundaje et al., 2015) and the Encyclopedia of DNA Elements (ENCODE Project Consortium, 2012) .
To achieve our goal, we employ targeted capture (Gnirke et al., 2009) of 71 AD candidate genes in combination with deep, massively parallel next-generation sequencing (McKernan et al., 2009 ). This approach is technically similar to exome sequencing, but captures the entire gene and its flanking regions, including putative regulatory regions. This method can identify several types of genetic variants, including common and rare variants, which allowed us to investigate the role these variants may play in AD. To our knowledge, this is the first sequencing study of AD to examine entire genes, including introns and gene promoters, regions upstream of genes that assist with gene transcription, and regulatory regions; areas not previously covered by alcohol exome studies. Publically available resources, such as the Roadmap Epigenomics Project (Kundaje et al., 2015) , will be used to aid in the interpretation of AD findings outside exons (Edwards et al., 2013) .
As there may be a large number of causal risk variants that have small effects (Manolio et al., 2009) , we also tested sets of variants for association with AD. These risk variants may be too small to detect individually because of low statistical power, but may be detectable when their effects are aggregated (Wang et al., 2011) . Recently, methods have been developed that test the association of a set of variants with a phenotype of interest, including, but not limited to, risk profile scoring and gene-set testing. One disadvantage of these methods is that the sets are often formed based on nominal significance with AD, which can make the results difficult to interpret as there is no link to how these sets affect gene function or expression. Instead, our sets were formed based on biological function (e.g., likely to affect regulatory function or protein coding). By grouping variants in this manner, our results are more interpretable and allowed generation of functional hypotheses about how the variant set may influence AD.
MATERIALS AND METHODS

Samples
The sequenced sample comprises 363 subjects from the Virginia Twin Study on Adolescent Behavioral Development (VTSABD) (Meyer et al., 1996) and 443 subjects from the Minnesota Twin Family Study (MTFS) (Iacono et al., 1999; Miller et al., 2012) . Both of these studies are twin samples, however, based on random selection, only 1 subject per twin pair was sequenced. Table 1 provides summary descriptives data for each of the samples. The sequenced MTFS samples had a higher composition of males and monozygotic twins when compared to the VTSABD. All subjects were of European ancestry. Blood samples were collected from which DNA was extracted. Ethical committees in the United States approved all procedures, and all subjects provided written informed consent.
Measures
The phenotype considered in this study is a count of the number of AD symptoms as measured by the DSM-IV (American Psychiatric Association, 1994). For both samples, the AD symptoms were assessed by in-person interviews. In the VTSABD, the DSM-IV was assessed when the subjects were 18 to 31 years old. The MTFS sample was assessed on AD at multiple time points, but to be comparable to VTSABD, only measures from when the subjects were 18 to 31 years old were used. Longitudinal measures, if available, were collapsed across subject by taking the maximum count of AD symptoms endorsed between 18 and 31 years of age. The age at which this maximum occurred was used as a covariate in the analyses. AD symptom count was treated as a quantitative trait in the following analyses.
Descriptive data for each sample are shown in Table 1 . The samples had comparable rates of individuals reporting using alcohol ever, ever receiving an AD diagnosis, and endorsing an AD symptom.
Sequencing
We used the solution-based hybridization targeted capture technology (SureSelectXT; Agilent, Santa Clara, CA) to target entire genes and AE5 kb of their flanking regions. In this method, a library of synthetic oligonucleotides (baits) complementary to the sequence of interest is custom designed and manufactured (Gnirke et al., 2009) . These baits are then used to pull down the desired genomic regions from fragmented genomic DNA samples. Library design and bait tiling were carried out using Agilent eArray.
The loci included in our targeted capture library were as follows: genes identified through published GWAS of alcohol (Schumann et al., 2011) ; human alcohol dehydrogenases (N = 8) and aldehyde dehydrogenases (N = 20), the key enzymes involved in alcohol metabolism (Edenberg, 2007) ; reward system genes, including dopaminergic and opioid receptors and related metabolic genes (N = 14); and the remaining space on the array was filled through prioritization of remaining candidate genes as described in the Supporting Information (N = 29). After collapsing neighboring genes into single loci and removing difficult-to-align repetitive elements, our selection encompassed 71 unique loci, covering a total of 5.5 Mb.
The libraries were paired-end sequenced (75 bp + 35 bp reads) on the SOLiD 5500xl (Life Technologies, Carlsbad, CA). The sequence reads were aligned to the human genome (build hg19/ GRCh37) using Bioscope 1.3 (Life Technologies) that aligns in color space. After alignment, quality control (QC) measures were implemented including dropping subjects with low mapped reads (<1 million) and fold enrichment (<365). Mean coverage across the targeted regions for each individual was 789, with at least 109 coverage for 88.2% of the targeted regions, an average fold enrichment of 393.8, and 97.9% of baits covered. This level of coverage is very high for color space data, where 2 color call errors must occur by chance in adjacent positions before a single-nucleotide polymorphism (SNP) is incorrectly called and therefore should result in fewer base calling errors relative to equivalent coverage on other sequencing platforms (McKernan et al., 2009 ).
Variant Calling and Annotation
The variants were called and filtered using GATK (McKenna et al., 2010) according to best practices recommendations (DePristo et al., 2011; Van Der Auwera et al., 2013) . Specifically, we employed variant quality score recalibration to filter variants. We defined rare variants as having a minor allele frequency (MAF) < 0.01 and common variants as MAF ≥0.01.
All variants passing QC were annotated to examine if variants overlapped with bioinformatic features from the following databases: UCSC Genome Browser and GENCODE (for a full list of annotations see Table S1 ). To determine their novelty, identified variants were compared with dbSNP v141 (Phillips, 2007) and the 1000 Genomes Database (Clarke et al., 2012 ) (1KG). Variants were also annotated for overlap with 15 chromatin states, elements that regulate gene transcription (Baker, 2011) , in liver and brain tissue from the anterior caudate, hippocampus, mid-frontal lobe, and substantia nigra regions, which are all known to be involved with alcohol addiction (Bassareo et al., 2003; George et al., 2001; Ozsoy et al., 2013; Wrase et al., 2008) . See Supporting Information for a description of the chromatin states and how they were generated by the Roadmap Epigenomics Project (Kundaje et al., 2015) .
Statistical Analyses
Individual Variants. To determine if AD symptom count was associated with any single, common variant, we performed single-locus tests on all common variants passing QC filters using a linear regression model of additive effects in PLINK (Purcell et al., 2007) for the VTSABD and MTFS separately. Sex, age and 10 ancestry principal components (PCs; see Supporting Information) were included as covariates to control for sex differences and ancestry. The results from each dataset were then meta-analyzed using a fixed effects model in PLINK (Purcell et al., 2007) . We used a false discovery rate (FDR)-based approach to declare significance (Supporting Information). Briefly, we set an FDR threshold of 0.10 (Van Den Oord and Sullivan, 2003) for declaring genomewide significance that was implemented using q-values (Black, 2004) , which are FDRs calculated using the p-value of the markers as thresholds for declaring significance.
Sets of Variants.
Variant set-based association tests were performed using SKAT (Lee et al., 2012b) to identify sets of variants associated with AD symptom count. To form the sets, we used the annotations described in Variant Calling and Annotation. Taking the POLYPHEN-Damaging annotation as an example, within a given gene, all variants that had a POLY-PHEN-Damaging annotation were used to form the variant set. Those variants that did not have the annotation were not included in the set. If a set had only 1 variant that overlapped with a specific annotation in a given gene, then it was excluded from testing as the test would be equivalent to the individual variant test described above. By forming variant sets based on their overlap with a specific annotation, we are able to test whether variants that cause damaging amino acid changes or variants involved in regulatory processes or some other function could potentially be causal.
The VTSABD and MTFS were analyzed together as a meta-analysis to increase power and ensure that the same variants were used to form each set. An indicator variable that identified which study a subject originated from was included as a covariate to address any potential study-related effects. Sex, age, and 10 PCs were also included as covariates in this analysis. We tested the combined effects of common and rare variation in SKAT as described in Ionita-Laza and colleagues (2013). Briefly, the effect of common and rare variants is assessed separately and then the corresponding test statistics are combined using weights such that common and rare variants contribute equally to the overall test statistic. We required that all variants be polymorphic in both the VTSABD and MTFS to avoid singleton or rare variants in 1 dataset overly influencing the results. In total, 1,312 sets were tested for association with AD.
Previous studies have shown that under certain conditions SKAT can be biased when calculating p-values (Ionita-Laza et al., 2013; Lee et al., 2012a) . To check the significance of the results with q-values < 0.30, we conducted 100,000 permutations. Specifically, we permuted the phenotypes in each sample separately to preserve the genetic architecture in each study. The analyses were then conducted on the combined permuted data.
RESULTS
Variant Calling
In the 71 loci investigated, we identified 25,922 variants of which 18,442 (71.4%) were rare and 12,417 (47.9%) were novel. Of these novel variants, 73.1% were singleton variants. After removing all singleton variants and requiring that variants be polymorphic in both samples, there were 18,028 variants remaining for analysis. For a complete list of variants investigated, see Table S2 .
Individual Variants
The quantile-quantile (QQ) plot of the individual, common variant meta-analysis results (Fig. 1) shows that the distribution of p-values is generally on a straight line, indicating the expected p-value distribution under the null hypothesis assuming no effects of the markers. If there were evidence of a true association between these variants and AD symptom count, we would see points in the upper right corner of the plot. However, there is no evidence to support an association between these variants and AD symptom count.
Examining the top 10 variants (Table S3) confirms that none of the common variants were significant at the stringent q-value < 0.1 level, nor at a very liberal threshold of q-value <0.95.
Sets of Variants
The QQ-plot, Fig. 2 , shows evidence for association as indicated by the points above the confidence interval in the upper, right corner of the plot. The results show ( Table 2) that there are 2 significant sets associated with AD symptom count at the q-value <0.10 level and several suggestive sets. Of the results listed in Table 2 , only 1 set involved variants that could potentially affect protein coding (i.e., SLC6A3 POLYPHEN-Damaging sets). Three sets involved regulatory annotations based on chromatin activity classifications, and a further 6 involved other annotations indicative of regulatory potential such as promoter regions, CpG shores, noncoding RNA, or enhancer regions. The list of variants in each set listed in Table 2 is provided in Table S4 .
Our results confirm the finding from previous studies that the results from SKAT can be biased. Specifically, we observed a k of 0.797. Values less than 1 suggest that the observed test statistics are smaller than expected when compared with the complete null hypothesis assuming no effect for any of the sets. The permutation p-values were comparable to the observed p-values from SKAT (Table 2) , with the permutation p-values being slightly more conservative in some cases, and unrelated to the variant set size (Fig. S1 ).
DISCUSSION
We tested variants in 71 candidate loci plausibly associated with AD. Results showed that no single common variant was associated in any of the loci, which is unsurprising given that we do not have the large sample size needed to detect a small effect of a common variant (N > 10,000). This is also consistent with other GWASs of AD where either no variants were found to be significantly associated or the associated variants only explained a small portion of AD risk (Hart and Kranzler, 2015) . We then tested if sets of variants formed on the basis of overlap with biologically meaningful annotations within a given locus were associated with AD. These analyses identified sets overlapping with potentially functional (affecting protein coding or regulatory processes) annotations that were significantly associated with AD. Six of the top variant sets were located in alcohol or aldehyde dehydrogenase genes. These genes encode for different enzymes that are involved in alcohol metabolism. Some of the strongest and most widely replicated genetic associations for AD have occurred with common variants in these genes. There has been limited work to date examining the role of rare variants in these genes in AD. Only 1 study examined rare variants and found an association with rare variants across the entire alcohol dehydrogenase gene cluster (Zuo et al., 2013c) . Our variant set findings suggest a role for both common and rare variants in these genes. Indeed, a recent commentary has called for the need to examine genetic variation across the entire allelic spectrum to identify risk variants for AD (Edenberg and Foroud, 2014) . This strategy has proved successful across a number of other disorders such as, for example, nicotine dependence (Olfson et al., 2016) and schizophrenia (Chang et al., 2016) , suggesting that there is the potential for a more general trend of both common and rare variants playing a role in risk.
Three of the top variant sets involved the dopamine transporter gene, SLC6A3, also known as DAT1, which has been extensively studied for association with AD because of dopamine's role in reward processes. Most previous genetic studies have focused on the 40-base-pair variable-number tandem repeat in the 3 0 -untranslated region of the gene. There has been mixed evidence for association of genetic variants in this region with AD (Du et al., 2011) , although a recent meta-analysis found a significant association with the A9 genotype (Ma et al., 2016) . Our variant set findings implicate the opposite end of this gene, specifically the promoter region, suggesting that genetic variants in this region of the gene may influence AD by regulating gene expression. Bioinformatic analyses of SLC6A3 have shown an abundance of CpGs in the promoter implicating DNA methylation as the regulatory mechanism (Shumay et al., 2010) . DNA methylation (Kerkel et al., 2008) has been shown to be regulated by genetic variation and there is ample evidence suggesting that this in turn may affect gene regulation/expression. In the specific context of addiction, a recent study showed that different genotypes influence epigenetic modifications and gene transcription differently in response to cocaine (Vasiliou et al., 2012) .
Only 2 studies have examined the exons of the loci considered here with the goal of identifying causal variants for AD in subjects of European ancestry, to our knowledge. These studies also found that single, common variants are not causal (Vrieze et al., 2014; Zuo et al., 2013a) . Only the Vrieze and colleagues (2014) study examined if a variant set was associated with AD. The sets they examined, nonsynonymous rare variants, were not significantly associated with AD. This is equivalent to our nonsynonymous rare variant findings which is unsurprising given that the MTFS is a subset of the subjects in the Vrieze and colleagues (2014) study. As these previous studies focused only on exons, they would have missed 65 of 73 (89.1%) variant set findings with p-value < 0.05 found outside protein coding regions. To our knowledge, no previous investigation has examined the role regulatory variant sets may play in AD.
Our findings must be interpreted in the context of the potential limitations. One limitation is that our results suggest potential mechanisms through which the variant sets may affect AD, rather than proving the mechanism. Possible next steps to test the suggested mechanisms include testing these variants sets in an independent sample and examining the function of significant sets in targeted laboratory experiments. We explored whether some of variants included in the top variants sets influenced gene expression using GTEx (Carithers and Moore, 2015) (Table S6 ) and found several "N Rare" and "N Common" are the number of rare variants (MAF < 0.05) and common variants (MAF ≥ 0.05) included in the tested set. "p-value" and "q-value" are the observed p-values and q-values from the test of whether the set of variants that overlap with the specified genomic feature within the given gene is associated with AD symptom count. "Perm. p-value" are the permutation p-values. "Gene" indicates that the name of the gene the variant set falls within the boundary of as defined by RefSeq. "Feature" describes genomic attributes under consideration. "Promoter" indicates the variant is within 5 kb of a transcription start site of the given gene; "Noncoding RNA" indicates a functional RNA molecule that is not translated into a protein; "CpG Shore" is AE2 kb flanking a CpG Island; "POLYPHEN-Damaging" indicates that the variant is predicted to cause a deleterious amino acid substitution by PolyPhen2 (Adzhubei et al., 2010) . Chromatin states are indicated by the following format: chromatin state name-tissue type (region if tissue is brain). Possible chromatin states are active transcription start site (TSS), flanking active TSS, transcription at gene 5 0 and 3 0 , strong transcription, weak transcription, genic enhancer, enhancer, ZNF genes and repeats, heterochromatin, bivalent/poised TSS, flanking bivalent TSS/enhancer, bivalent enhancer, repressed polycomb, weak repressed polycomb, and quiescent. The brain regions examined for chromatin states were as follows: AC, anterior caudate; HM, hippocampus; MFL, mid-frontal lobe; and SN, substantia nigra.
variants are expression quantitative trait loci. Other potential methods to explore the functional effects of these variants include targeted genome editing where the specific variant of interest is artificially engineered against a standard cell line background (e.g., CRISPR-Cas9) and the functional effects are observed (De Souza, 2012) , or targeted chromatin immunoprecipitation assays of regulatory elements such as transcription factor binding sites and histone marks overlapping with the significant results.
In conclusion, we did not find a single, common variant that was significantly associated with AD in any of the 71 susceptibility loci considered. However, we identified specific sets of variants within some candidate genes as being potentially causal. We found interesting protein coding variant sets; however, they do not account for all signals and it is likely that other variants also contribute via a regulatory role.
FUNDING/SUPPORT
This work was supported by the National Institutes of Health (R01 DA024413, R01 MH045268, R01 MH068521, R01 DA036216, R01 DA05147, R01 DA024417, R01 AA09367, R25 DA026119, and K01 AA021266 to SLC). The authors report no conflicts of interest.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article: Fig. S1 . Plot of the number of variants in a set versus the observed p-Value from SKAT. Table S1 . Description of bioinformatic annotations and their source. Table S2 . Descriptives of candidate genes investigated. Table S3 . Top 10 common, individual variant results. Table S4 . List of variants in each set listed in Table 2 . Table S5 . Variant set association results for individual datasets. Table S6 . GTEx results for variants in sets listed in Table 2 .
